In the article by Amersi and coworkers, beginning on page 638 of the February 1, 2008, issue of Clinical Cancer Research, the legend to Figure 6 was incorrect. Figure 6 and the correct legend appear below.
CCR9(+) Melanoma Cell Migration and Invasive Responses to CCL25. A, cell migration of representative melanoma lines (ME-17, 21, 79, and 87) that were CCR9(+). Stimulation with CCL25 (100 ng/ml) significantly increased the number of migrating CCR9(+) cells (both P < 0.001) as determined by the migration assay. □ No treatment; ▪ CCL25 treatment. CCR9(-) melanoma line (ME_35) showed no response to CCL25. B, cell Matrigel matrix invasion assay of representative melanoma lines not treated □ and treated 
with CCL25, respectively (P < 0.002). Addition of the anti-CCR9 antibody (1μg/ml) resulted in a significant decrease in the number of cells that invade across the Matrigel matrix in response to CCL25 (P < 0.004); ▪ CCL25 + anti-CCR9 Ab. C, qRT analysis of representative CCR9(+) melanoma lines was performed after CCR9 siRNA and control siRNA transfection. After siRNA treatment, a significant decrease in CCR9 expression is seen in ME_21 (P = 0.002) cells and ME-17 (P = 0.004) cells: ▪ ME-21 cell line; ME-17 cell line. D, Cell migration assay of two representative melanoma lines after CCR9 siRNA transfection following treatment with CCL25; Y-axis: number of cells per high-power field. Controls include CCL25 treatment alone, with laminin siRNA or scrambled siRNA. There was a significant decrease in CCR9 siRNA-transfected cells migrating in response to CCL25 (P < 0.004 and P < 0.01, respectively): ▪ ME-21 cell line; ME-17 cell line.
CCR9(+) Melanoma Cell Migration and Invasive Responses to CCL25. A, cell migration of representative melanoma lines (ME-17, 21, 79, and 87) that were CCR9(+). Stimulation with CCL25 (100 ng/ml) significantly increased the number of migrating CCR9(+) cells (both P < 0.001) as determined by the migration assay. □ No treatment; ▪ CCL25 treatment. CCR9(-) melanoma line (ME_35) showed no response to CCL25. B, cell Matrigel matrix invasion assay of representative melanoma lines not treated □ and treated with CCL25, respectively (P < 0.002). Addition of the anti-CCR9 antibody (1μg/ml) resulted in a significant decrease in the number of cells that invade across the Matrigel matrix in response to CCL25 (P < 0.004); ▪ CCL25 + anti-CCR9 Ab. C, qRT analysis of representative CCR9(+) melanoma lines was performed after CCR9 siRNA and control siRNA transfection. After siRNA treatment, a significant decrease in CCR9 expression is seen in ME_21 (P = 0.002) cells and ME-17 (P = 0.004) cells: ▪ ME-21 cell line; ME-17 cell line. D, Cell migration assay of two representative melanoma lines after CCR9 siRNA transfection following treatment with CCL25; Y-axis: number of cells per high-power field. Controls include CCL25 treatment alone, with laminin siRNA or scrambled siRNA. There was a significant decrease in CCR9 siRNA-transfected cells migrating in response to CCL25 (P < 0.004 and P < 0.01, respectively): ▪ ME-21 cell line; ME-17 cell line.
RSS Feeds